公开(公告)号：EP4493197A2

公开(公告)日：2025-01-22

申请号：EP23771701.2

申请日：2023-03-17

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： CHEN, Robert ,  WANG, Sean ,  AMAYA, Laura ,  CHANG, Howard Y.

IPC: A61K31/713 ,  A61K48/00 ,  C12N15/79 ,  A61K45/00

公开(公告)号：EP4488292A1

公开(公告)日：2025-01-08

申请号：EP23760185.1

申请日：2023-02-27

Applicant: Teijin Pharma Limited ,  University Public Corporation Osaka

Inventor： EGUCHI, Hiroshi ,  TOMIYAMA, Takami ,  UMEDA, Tomohiro

IPC: C07K16/28 ,  A61K31/713 ,  A61K35/12 ,  A61K38/02 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P25/00 ,  A61P25/28 ,  A61P37/04 ,  A61P43/00 ,  C07K14/705 ,  C07K16/46 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/06 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08

Abstract: The present invention provides: an anti-gpNMB antibody that binds to gpNMB and affects the same and that has an effect of such as removal of dysfunctional microglia; and a use application of the anti-gpNMB antibody. The anti-gpNMB antibody specifically binds to at least one site in a region from a PMEL-CAF-like domain to a PKD domain of gpNMB.

公开(公告)号：EP4483900A1

公开(公告)日：2025-01-01

申请号：EP23759873.5

申请日：2023-02-17

Applicant: Institute of Rheological Function of Food Co., Ltd. ,  Kyushu University, National University Corporation

Inventor： FUJINO Takehiko ,  MAWATARI Shiro ,  HONSHO Masanori ,  OKAUCHI Tatsuo

IPC: A61K45/00 ,  A61K31/045 ,  A61P35/00 ,  C12Q1/06 ,  G01N33/15 ,  G01N33/50

Abstract: The anticancer agent of the disclosure contains an ATP8B2 inhibitor.

公开(公告)号：EP4483899A1

公开(公告)日：2025-01-01

申请号：EP23760086.1

申请日：2023-02-24

Applicant: Juntendo Educational Foundation ,  Meiji Seika Pharma Co., Ltd.

Inventor： KOMATSU, Norio ,  ISHIDA, Yoji ,  ARAKI, Marito ,  TSUCHIYA, Toshiyuki ,  CHIKADA, Tsubasa ,  IMAI, Misa ,  FUKASAWA, Hiroshi

IPC: A61K39/395 ,  A61K31/17 ,  A61K31/519 ,  A61K38/21 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07K16/46 ,  C07K16/18

Abstract: Provided is a pharmaceutical which exhibits sufficient anticancer effects by using an antibody which binds to a mutant CALR protein and another anticancer agent in combination. Provided is a pharmaceutical for preventing and/or treating a cancer, comprising (A) an antibody which specifically binds to a mutant calreticulin protein or a functional fragment thereof and (B) at least one drug selected from the group consisting of an alkylating agent, a platinum preparation, an antimetabolite, a ribonucleotide reductase inhibitor, a nucleotide analog, a topoisomerase inhibitor, a microtubule polymerization inhibitor, an antitumor antibiotic, an interferon, a cytokine preparation, a molecular targeting drug, a nucleic acid synthesis inhibitor, a JAK inhibitor, and a cancer immunotherapeutic agent in combination.

公开(公告)号：EP4480474A1

公开(公告)日：2024-12-25

申请号：EP23796357.4

申请日：2023-04-25

Applicant: Eisai R&D Management Co., Ltd.

Inventor： FUKUSHIMA Kazuyuki

IPC: A61K31/18 ,  A61K31/198 ,  A61K45/00 ,  A61P25/16

Abstract: Disclosed is a pharmaceutical composition for treatment of Parkinson's disease comprising N-[(1S)-2,2,5,7-tetrafluolo-2,3-dihydro-1H-inden-1-yl]sulfamide represented by formula (1) or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP4479050A1

公开(公告)日：2024-12-25

申请号：EP23711358.4

申请日：2023-02-15

Applicant: Tesaro, Inc.

Inventor： SANAI, Nader ,  MEHTA, Shwetal

IPC: A61K31/454 ,  A61K45/00 ,  A61P35/00

公开(公告)号：EP4473970A1

公开(公告)日：2024-12-11

申请号：EP23780756.5

申请日：2023-03-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： KATO Yu ,  KUME Masahiko ,  HORI Yusaku ,  ADACHI Yusuke

IPC: A61K31/53 ,  A61K31/519 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00

Abstract: The present invention provides a pharmaceutical composition for treating a tumor, the pharmaceutical composition comprising (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl} methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydr o-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is administered in combination with an RAS inhibitor.

公开(公告)号：EP4472664A1

公开(公告)日：2024-12-11

申请号：EP23737185.1

申请日：2023-01-09

Applicant: Anda Biology Medicine Development (Shenzhen) Co., Ltd.

Inventor： HU, Landian ,  KONG, Xiangyin ,  ZHANG, Yuchao ,  WANG, Rongjing ,  WU, Zhenchuan

IPC: A61K39/39 ,  A61K31/00 ,  A61K45/00 ,  C12Q1/6809 ,  A61P37/00 ,  A61P35/00 ,  A61P31/00

公开(公告)号：EP4035678B8

公开(公告)日：2024-12-04

申请号：EP20869232.7

申请日：2020-09-25

Inventor： YOSHIOKA, Hiroki ,  HAMURA, Ken ,  OSAKAMA, Kazuki ,  NISHIYAMA, Nobuhiro

IPC: A61K39/395 ,  A61K45/00 ,  A61P43/00 ,  C08G65/333 ,  C08G81/00 ,  C07K5/06 ,  C07K5/08 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/46 ,  C07K14/52 ,  C07K14/575 ,  C07K16/00 ,  A61K47/60 ,  A61K47/64 ,  C12N15/115 ,  A61K38/02 ,  A61K38/19 ,  A61K38/22

公开(公告)号：EP4467157A1

公开(公告)日：2024-11-27

申请号：EP23743377.6

申请日：2023-01-23

Applicant: Louis Pasteur Center for Medical Research

Inventor： IWAKURA, Yoichiro ,  CHUNG, Soo-Hyun ,  KUBO, Masato ,  SUN, Haiyang ,  YABE, Rikio

IPC: A61K45/00 ,  A61K39/395 ,  A61P1/04 ,  A61P35/00 ,  C07K16/28

Abstract: A pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumor, the pharmaceutical composition comprising a dendritic cell immunoreceptor inhibitor or a binding inhibitor between a dendritic cell immunoreceptor and an asialo-biantennary N-glycan, and a pharmaceutically acceptable carrier.